Salute e Benessere
Aktiia secures $42 million in Series B funding round and rebrands to Hilo
The latest investment builds on a period of significant momentum for the company during which it has achieved several major milestones, including securing CE marking for its innovative mobile phone camera blood pressure monitoring technology, securing regulatory approvals in Canada , Australia and Saudi Arabia , achieving 76% compounded annual revenue growth, and completing a pivotal clinical trial ahead of its U.S. FDA application submission. This Series B funding will fuel continued product innovation, expansion into new markets and the build out of its blood pressure intelligence platform to support enterprise use cases.
Alongside this funding, Aktiia is introducing its new brand identity: Hilo - a rebrand which reflects the company's global ambition to make cuffless, clinically validated blood pressure monitoring universally accessible and effortless. The transition to Hilo marks an important milestone in the company's journey, aligning with its vision of healthier blood pressure for all, while continuing to deliver the trusted technology and reports that have been central to its platform.
With more than 120,000 devices sold, Hilo has already established itself as a stand-out in the health tech space. The company has developed a foundation Machine Learning model specifically designed for blood pressure. The model has been trained on tens of billions of optical signals from real-world users and further refined with hundreds of millions of calibration points, strengthening its position as the leader in the emerging cuffless blood pressure monitoring (CBPM) category.
."
Aktiia, now trading under Hilo , was established in 2018 to transform how blood pressure is measured and therefore managed. By integrating advanced AI algorithms with extensive datasets, Hilo's cuffless blood pressure monitoring (CBPM) products offer convenient, valuable reports to give both individuals and healthcare professionals a useful picture of their blood pressure. The company's foundation model for blood pressure has been trained on billions of optical signals and hundreds of millions of readings across more than 120,000 users, underscoring its leadership in the CPBM category. The company's multidisciplinary team, composed of experts with extensive experience in biomedical signal processing, has contributed to over 120 peer-reviewed publications and holds more than 35 patents. Headquartered in Switzerland , Hilo continues to expand its global presence, transforming how blood pressure is understood and managed.
Photo - https://mma.prnewswire.com/media/2678061/Aktiia_Hilo_Transition.jpg
Logo - https://mma.prnewswire.com/media/2678060/Hilo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/aktiia-secures-42-million-in-series-b-funding-round-and-rebrands-to-hilo-302444824.html